The tolerability and effects of AZD8848 in allergic asthma subjects challenged with inhaled allergen

Study identifier:D0540C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, placebo-controlled, randomised, parallel group, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma subjects challenged with an inhaled allergen.

Medical condition

Allergic Asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD8848, Placebo

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Oct 2009
Primary Completion Date: 01 Feb 2011
Study Completion Date: 01 Dec 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2016 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria